To keep perspective, the fact that other cholesterol-lowering statindrugs like Lipitor and Crestor are more potent probably factored into this decision if the top dose of Zocor were the only option, the FDA might have kept it.
The researchers aim to recruit 150 women under the age of 70 with type 2 diabetes who have not had a period for at least a year, and who have been taking cholesterol-lowering statindrugs for at least 12 months.